Research

Hormonal

Newer GLP-1 and dual-agonist obesity medications produce significant weight loss (15-21%) and metabolic benefits, but discontinuation leads to weight regain.

Use GLP-1 medications as a long-term tool for weight management, not a short-term fix. Be prepared to continue treatment to maintain weight loss, as stopping often leads to regain.

GoodQualifiesHIGH confidence
Semaglutide... produces an average weight loss of about 15%. Tirzepatide... goes even further, with average weight loss approaching 21%... if these medications are stopped, weight regain can recur and metabolic outcomes worsen again [25].
Kristen Frederiksen et al. · Obesity Pillars · 2025

Why this rating

Cites FDA approvals and clinical trial data for specific drugs.

Source

Obesity pillars roundtable: Better together - combined obesity medicine and metabolic surgery care for the treatment of obesity

Kristen Frederiksen et al. · Obesity Pillars · 2025

DOI 10.1016/j.obpill.2025.100232

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →